Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
adverse effects
colorectal cancer
patient selection
treatment efficacy
trifluridine/tipiracil
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
15
7
2020
Statut:
ppublish
Résumé
Trifluridine/tipiracil is available on the Australian Pharmaceutical Benefits Scheme for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents. This article reviews trifluridine/tipiracil clinical data and presents practical information on its use in the management of refractory mCRC in Australia. Whereas the primary mechanism of action of fluoropyrimidines such as fluorouracil (5-FU) and capecitabine is enzyme inhibition of nucleotide synthesis, trifluridine/tipiracil primarily acts by incorporation into DNA, resulting in DNA dysfunction. Trifluridine/tipiracil has activity in patients with 5-FU-resistant tumors and can be considered in patients with prior intolerance or toxicity to 5-FU. In the pivotal phase III RECOURSE trial evaluating trifluridine/tipiracil in chemotherapy-refractory mCRC, efficacy benefits were observed across all a priori prognostic subgroups including those defined by age (≥65 and ≥75 years), geographical origin, primary tumor site or KRAS status. Trifluridine/tipiracil therapy benefits appropriately selected patients who have an ECOG performance status of 0 or 1, with no more than mild hepatic impairment or mild-to-moderate renal impairment, and who are capable of adhering to oral therapy safely. Appropriate dosing, monitoring for adverse events and effective management of side effects are essential.
Substances chimiques
Drug Combinations
0
Pyrrolidines
0
trifluridine tipiracil drug combination
0
Uracil
56HH86ZVCT
Thymine
QR26YLT7LT
Trifluridine
RMW9V5RW38
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-12Informations de copyright
© 2020 John Wiley & Sons Australia, Ltd.
Références
Australian Institute of Health and Welfare. Cancer in Australia: in brief 2019. Cancer series no. 122. Cat. no. CAN 126. Canberra: AIHW. 2019.
Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386-1422.
Cancer Council Australia Colorectal Cancer Guidelines Working Party. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. 2018 Sydney: Cancer Council Australia. Available from: https://wiki.cancer.org.au/australia/Guidelines:Colorectal_cancer. Accessed 4 June 2019.
Messersmith WA. NCCN Guidelines updates: Management of metastatic colorectal cancer. J Natl Compr Canc Netw. 2019;17:599-601.
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381:1632-1643.
Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773-779.
Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909-1919.
Servier Laboratories (Australia) Pty Ltd. LONSURF (trifluridine/tipiracil) Product Information.
Matsuoka K, Iimori M, Niimi S, et al. Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks. Mol Cancer Ther. 2015;14:1004-1013.
Lyseng-Williamson KA, Burness CB, Duggan ST. Trifluridine/tipiracil in metastatic colorectal cancer: A guide to its use. Drugs Ther Perspect. 2017;33:110-118.
Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: A review of the mechanism of action. Cancer Treat Rev. 2015;41:777-783.
Van Cutsem E, Mayer RJ, Laurent S, et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63-72.
Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13:993-1001.
Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: The TERRA Study. J Clin Oncol. 2018;36:350-358.
Falcone A, André T, Edeline J, et al. O-013 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study. Ann Oncol. 2018;29:O-013 (abstract and poster).
Taieb J, Price TJ, Ciardiello F, et al. Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study. J Clin Oncol. 2019;37:638 (abstract and poster).
Van Cutsem E, Falcone A, Garcia-Carbonero R, et al. Proxies of quality of life in metastatic colorectal cancer: Analyses in the RECOURSE trial. ESMO Open. 2017;2:e000261.
Tabernero J, Van Cutsem E, Ohtsu A, et al. QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer. ESMO Open. 2017;2:e000284.
Van Cutsem E, Ohtsu A, Lopez Busto N, et al. Time to grade ≥3 adverse events in pts receiving trifluridine/tipiracil (TAS-102). J Clin Oncol. 2017;35:788 (abstract and poster).
Mayer RJ, Van Cutsem E, Yoshino T, et al. Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34 (suppl):e15021 (abstract).
Tomita Y, Karapetis CS, Ullah S, et al. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. Acta Oncol. 2016;55:480-485.
Semira C, Wong HL, Field K, et al. Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: Is clinical practice following the evidence? Intern Med J. 2019;49:446-454.
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-312.
Abrahao ABK, Ko YJ, Berry S, et al. A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: A systematic review and network meta-analysis. Clin Colorectal Cancer. 2018;17:113-120.
Patel AK, Ng K, Duh MS, et al. Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A single institution retrospective study. J Clin Oncol. 2019;37:592 (abstract and poster).
Masuishi T, Taniguchi H, Hamauchi S, et al. Regorafenib versus trifluridine/tipiracil for refractory metastatic colorectal cancer: A retrospective comparison. Clin Colorectal Cancer. 2017;16:e15-e22.
Moriwaki T, Fukuoka S, Taniguchi H, et al. Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): A Japanese society for cancer of the colon and rectum multicenter observational study. Oncologist. 2018;23:7-15.
Sueda T, Sakai D, Kudo T, et al. Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies. Anticancer Res. 2016;36:4299-4306.
Chibaudel B, Tournigand C, Bonnetain F, et al. Platinum-sensitivity in metastatic colorectal cancer: Towards a definition. Eur J Cancer. 2013;49:3813-3820.
Suenaga M, Mizunuma N, Matsusaka S, et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther. 2015;9:3099-3108.
Cremolini C, Rossini D, Dell'Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: A phase 2 single-arm clinical trial. JAMA Oncol. 2019;5:343-350.
Arnold D, Prager GW, Quintela A, et al. Beyond second-line therapy in patients with metastatic colorectal cancer: A systematic review. Ann Oncol. 2018;29:835-856.
Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer. 2019;109:70-83.
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520.
Innocenti F, Ou FS, Qu X, et al. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol. 2019;37:1217-1227.
Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol. 2019;37:1460-1469.
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738-746.
Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518-530.
Yamashita F, Komoto I, Oka H, et al. Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse. Cancer Chemother Pharmacol. 2015;76:325-333.
Kimura M, Usami E, Iwai M, et al. Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy. Pharmazie. 2017;72:49-52.
Nishina T, Yoshino T, Shinozaki E, et al. Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030). J Clin Oncol. 2016;34 (suppl):abstr 3557 (abstract).
Kasi PM, Kotani D, Cecchini M, et al. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A cohort study. BMC Cancer. 2016;16:467.
Pavlakis N, Tran B, Ohtsu A, et al. Onset of neutropenia as an indicator of treatment response in the Phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) vs. placebo in patients with metastatic colorectal cancer. Poster presented at the Australasian Gastro-Intestinal Trials Group Annual Scientific Meeting; October 4-6, 2017; Cairns, Australia.
Dosing calendar. Available at: mydosingcalendar.com.au.
Cancer Institute NSW. eviQ Education. Colorectal metastatic trifluridine/tipiracil. Available at: https://www.eviq.org.au/medical-oncology/colorectal/metastatic/1940-colorectal-metastatic-trifluridine-tipiracil. Accessed 19 June 2019.
Saif MW, Rosen L, Rudek MA, et al. Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. Br J Clin Pharmacol. 2019;85:1239-1246.
Servier Laboratories (Australia) Pty Ltd. Data on file - Periodic Benefit Risk Evaluation Report (March 2018).
Kelly C, Bhuva N, Harrison M, et al. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer. 2013;49:2303-2310.
Servier Laboratories (Australia) Pty Ltd. LONSURF Dosing Ruler.
Lesniewski-Kmak K, Moiseenko V, Saunders M, et al. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. Ann Oncol. 2018;29 (suppl 5):mdy149.021 (abstract O-022).
Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437-1448.